CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

Moderna stock is falling after a sharp run-up in June that saw shares gain 48%.

Moderna (MRNA) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow ...

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Biotech is the story at midday Friday, and it’s not a pretty one for shareholders who chased the sector’s monster 2026 run.

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical ...

Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the ...

Global health organisation CEPI will give roughly $60 million to Moderna and two other groups to accelerate the development of shots ​against Ebola Bundibugyo, the deadly virus that has swept through ...

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ('LNP”) technology against Pfizer and BioNTec ...